Recombinant human granulocyte macrophage stimulating factor for injection

Recombinant human granulocyte macrophage colony-stimulating factor (rhGM-CSF) acts on hematopoietic progenitor cells to promote their proliferation and differentiation. Its important role is to stimulate the maturation of granulocytes and mononuclear macrophages, promote the release of mature cells into peripheral blood, and promote the various functions of macrophages and eosinophils.

Main ingredients: recombinant human granulocyte macrophage colony stimulating factor

This product is white or milky white loose body.

1. Prevent and treat leukopenia caused by tumor radiotherapy or chemotherapy. 2. Treat bone marrow hematopoietic dysfunction and myelodysplastic syndrome. 3. Prevent potential infectious complications during leukopenia. 4. Accelerate the recovery of neutrophil counts caused by infection.

1 After tumor radiotherapy and chemotherapy: This product can be used 24 to 48 hours after radiotherapy and chemotherapy are stopped. Dissolve this product with 1 ml of injection water (do not shake violently), and inject subcutaneously in the abdomen, outer thigh or upper arm deltoid muscle (the local skin should bulge about 1 cm2 after injection to allow the drug to be slowly absorbed), 3 to 10 μg/kg/day, for 5 to 7 days, and determine the maintenance dose based on the recovery speed and level of white blood cells. The next course of radiotherapy and chemotherapy can be carried out at least 48 hours after stopping this product. 2 Bone marrow transplantation: 5 to 10 μg/kg, intravenous drip once a day for 4 to 6 hours, and continue to be used until the absolute number of neutrophils is ≥1000/ml for 3 consecutive days. 3 Myelodysplastic syndrome/aplastic anemia: 3 μg/kg/day, subcutaneous injection, it takes 2 to 4 days to observe the initial effect of leukocytosis, and then adjust the dose to maintain the white blood cell count at the desired level, usually 10,000/μl.

The safety of this product is related to the dose and route of administration. Most adverse reactions are mild to moderate, and severe reactions are rare. The most common adverse reactions are fever, chills, nausea, dyspnea, and diarrhea, which can be relieved by general symptomatic treatment; followed by rash, chest pain, bone pain, and diarrhea. According to foreign reports, hypotension and hypoxia syndrome may occur at the first dose, but not in subsequent doses. Adverse reactions are more common with intravenous push and rapid drip, and doses greater than 32μg/kg/day.

1. Patients with a history of allergy to rhGM-CSF or any other component of the preparation. 2. Patients with autoimmune thrombocytopenic purpura.

1. This product can increase bone marrow toxicity when used with chemotherapy drugs. Therefore, it should not be used with chemotherapy drugs at the same time. It should be used 24 to 48 hours after the end of chemotherapy. 2. This product can cause a decrease in plasma albumin. Therefore, when using drugs with high plasma albumin binding at the same time, you should pay attention to adjusting the dosage of the drug. 3. For those who have injected immunoglobulin, they should wait for more than 1 month before inoculating this product.

Store at 2-8℃ away from light.

50μg/vial

Xiamen Amoytop Biotech Co., Ltd.

• Founded in:

  1996-08-07

• Address:

  No. 330, Wengjiao Road, Xinyang Industrial Zone, Haicang, Xiamen

• Tax NO.:

  913502002600603688

• Registered Funds:

  406.8 million yuan

• Website:

  Log in to view

• Email:

  Log in to view